Vera Therapeutics is trading 4.43% down at $30.18 after investors weighed its August 10 earnings report, which showed a $109.5 million second-quarter net loss despite an EPS beat.
- Operating expenses rose as TRUTAKNA commercialization began.
- Wedbush lowered its price target to $34 from $43 and maintained a neutral rating.
- The broader market is modestly weaker, but company-specific developments appear more significant.